Literature DB >> 12204526

A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization.

Jose Baselga1.   

Abstract

Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12204526     DOI： 10.1016/s1535-6108(02)00098-3

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  Immunological Approaches in the Treatment of Metastasized Breast Cancer.

Authors:  Volkmar Müller; Isabell Witzel; Elmar Stickeler
Journal:  Breast Care (Basel)       Date:  2009-12-16       Impact factor: 2.860

Review 2.  HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.

Authors:  Nadia Harbeck; Matthias W Beckmann; Achim Rody; Andreas Schneeweiss; Volkmar Müller; Tanja Fehm; Norbert Marschner; Oleg Gluz; Iris Schrader; Georg Heinrich; Michael Untch; Christian Jackisch
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

Review 3.  Advances in the management of HER2-positive early breast cancer.

Authors:  José Baselga; Robert E Coleman; Javier Cortés; Wolfgang Janni
Journal:  Crit Rev Oncol Hematol       Date:  2017-10-04       Impact factor: 6.312

4.  A growing family: adding mutated Erbb4 as a novel cancer target.

Authors:  Udo Rudloff; Yardena Samuels
Journal:  Cell Cycle       Date:  2010-04-15       Impact factor: 4.534

5.  HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms.

Authors:  Bart S Hendriks; H Steven Wiley; Douglas Lauffenburger
Journal:  Biophys J       Date:  2003-10       Impact factor: 4.033

Review 6.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

7.  The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.

Authors:  Jonathan R Walker; Pawan K Singal; Davinder S Jassal
Journal:  Exp Clin Cardiol       Date:  2009

8.  Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target.

Authors:  Abiodun Julius Arannilewa; Oluwaseun Suleiman Alakanse; Adesola Oluwaseun Adesola; Oluwaseyi Israel Malachi; Ifedayo Michael Obaidu; Emmanuel Ekun Oluwafemi; Emmanuel Damilola Afolayan; Patricia Folakemi Afere; Kayode Abdullateef Ayuba; Tolulope Oluwafemi Bolarinwa; George Oche Ambrose
Journal:  Bioinformation       Date:  2018-11-21

Review 9.  Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.

Authors:  Nathan Wd Lamond; Tallal Younis
Journal:  Int J Womens Health       Date:  2014-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.